Delving into the Latest Updates on Asciminib Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Asciminib, 阿思尼布, 阿西米尼

+ [7]

Target

Bcr-Abl

Action

inhibitors

Mechanism

Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases+ [1]

Active Indication

Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutationPhiladelphia chromosome-positive chronic myeloid leukemia in chronic phaseChronic Myelogenous Leukemia+ [13]

Inactive Indication-

Originator Organization

Novartis AG

Active Organization

Novartis Pharma AG

Novartis Pharmaceuticals Corp.China Novartis Institutes for BioMedical Research Co., Ltd.

+ [10]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (29 Oct 2021),

Philadelphia chromosome positive chronic myelogenous leukemia

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Fast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC20H19Cl2F2N5O3

InChIKeyHGCOOPLEWPBLOY-PFEQFJNWSA-N

CAS Registry2119669-71-3

The aim of this study is to support development of asciminib in the pediatric population (1 to < 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.

Start Date04 May 2026

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT07040982

/ Not yet recruitingPhase 1IIT

Pilot Study of Asciminib as a Maintenance Treatment Post Cellular Therapies in Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

This phase I trial tests the safety, side effects and best dose of asciminib as maintenance treatment for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) who have undergone cellular therapies such as hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR) T cell therapy. Maintenance treatment is given to help keep cancer from coming back after it has disappeared following initial therapy. Asciminib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving asciminib may be safe and tolerable as maintenance treatment for adult patients with Philadelphia chromosome positive ALL who have undergone cellular therapies.

Start Date01 May 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07039760

/ Not yet recruitingEarly Phase 1IIT

An Early Phase 1 Study of Asciminib With or Without Sildenafil for Brain Tumors

Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.

Start Date30 Apr 2026

Sponsor / Collaborator

Washington University School of Medicine

100 Clinical Results associated with Asciminib Hydrochloride

Login to view more data

100 Translational Medicine associated with Asciminib Hydrochloride

Login to view more data

100 Patents (Medical) associated with Asciminib Hydrochloride

Login to view more data

338

Literatures (Medical) associated with Asciminib Hydrochloride

01 Apr 2026·Hematology Transfusion and Cell Therapy

Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?

Review

Author: Alanazi, Majed A ; Jackson, Denise E ; Omar, Musab Ma

Asciminib represents a significant advancement in the treatment of chronic myeloid leukemia, establishing a novel therapeutic paradigm by specifically targeting the ABL1 myristoyl pocket, a mechanism distinct from that of conventional adenosine triphosphate-competitive inhibitors. Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies. Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further. The effectiveness of asciminib, combined with its capacity to overcome resistance through combination strategies with adenosine triphosphate-binding site tyrosine kinase inhibitors, establishes it as a focal point in emerging chronic myeloid leukemia treatment approaches. It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.

04 Mar 2026·Expert Review of Hematology

Addressing unmet needs in chronic myeloid leukemia in chronic phase treated with two or more tyrosine kinase inhibitors: insights from literature and Indian clinical practice

Review

Author: Saini, Kuldeep ; Jain, Rishi ; Gundeti, Sadashivudu ; Sharma, Lalit Mohan ; Bhattacharya, Jina ; Shetty, Disha ; Bagal, Bhausaheb ; Baul, Shuvra Neel ; Kumar, Sujeet ; Sharma, Vishnu ; Nair, Velu ; Malhotra, Hemant ; Nag, Arijit ; Verma, Shailendra Prasad ; Yadav, Sanjeev ; Jena, Rabindra Kumar

INTRODUCTION:

Chronic myeloid leukemia (CML) is a myeloproliferative disorder, usually diagnosed in its chronic phase (CP), often requiring life-long therapy. Despite the effectiveness of targeted therapy with tyrosine kinase inhibitors (TKIs), resistance or intolerance may occur, requiring a switch. The probability of achieving guideline-recommended cytogenetic and molecular responses declines from first (1 L) to second (2 L) and subsequent lines. About half of the patients receiving third line TKI treatment exhibit resistance or intolerance to prior TKIs. Post-2 L, patients experience non-durable responses, persistent adverse events, and a decreased quality of life.

AREAS COVERED:

This narrative review is based on targeted literature search in Medline via PubMed and expert clinical input from Indian hematologists to cover unmet needs of patients with CP-CML post-2 L of TKI therapy. We present an overview of the available clinical data, outline the challenges associated with treatment resistance and intolerance, identify gaps in patient management, and discuss personalized treatment approaches that could bridge these gaps and improve patient outcomes post-2 L.

EXPERT OPINION:

Management of CP-CML beyond 2 L remains a significant clinical challenge due to resistance, intolerance, and suboptimal long-term responses with currently available TKIs. Integrating newer agents like asciminib or ponatinib, can help overcome resistance and improve patient outcomes.

04 Mar 2026·Expert Review of Hematology

Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia

Review

Author: Kimura, Shinya ; Ureshino, Hiroshi

INTRODUCTION:

Chronic myeloid leukemia (CML) has been transformed by ATP-competitive BCR:ABL1 tyrosine kinase inhibitors (TKIs); however, resistance, intolerance, and long-term toxicity remain clinically relevant challenges, particularly in patients requiring prolonged therapy or multiple treatment lines. Asciminib, the first-in-class Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor, represents a paradigm shift by restoring physiologic ABL1 autoinhibition through allosteric binding.

AREAS COVERED:

This Special Report reviews the mechanistic basis, preclinical development, and clinical evidence supporting asciminib in CML. We summarize key data from pivotal trials, including ASCEMBL and ASC4FIRST, as well as emerging real-world studies, focusing on molecular response depth, safety, resistance mechanisms, and patient selection. Particular attention is paid to how STAMP inhibition differs from ATP-competitive TKIs in terms of selectivity, toxicity profile, and resistance patterns, and how asciminib can be positioned relative to ponatinib in later-line settings.

EXPERT OPINION:

Asciminib has established itself as an effective and generally well-tolerated option for patients with TKI-resistant or -intolerant CML and is poised to expand into earlier lines of therapy. Its ability to induce rapid and deep molecular responses with reduced off-target toxicity may have important implications for long-term disease control and future treatment-free remission (TFR) strategies. Ongoing studies will clarify its optimal sequencing, combination potential, and role in facilitating durable TFR.

160

News (Medical) associated with Asciminib Hydrochloride

08 Apr 2026

·www.biospace.com

Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data

iStock, cagkansayin Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it unlikely that another suitor could offer a counter-proposal to Merck’s outstanding $6.7 billion acquisition offer. When Merck unveiled its $6.7 billion buyout bid for Terns Pharmaceuticals last month, analysts called the deal a bargain for the pharma. William Blair even suggested that the price undervalued Terns and that a rival suitor could emerge. Now, new disclosures about the drug at the center of the acquisition have dampened that enthusiasm and revealed that Merck had once offered roughly $1 billion more. “The emergence of a higher bidder is unlikely,” William Blair told investors in a note on Tuesday, walking back its previous assessment of the acquisition. “We now believe that the Merck acquisition will be completed later this quarter.” Merck initiated its tender offer for Terns on the same day. The pharma had initially proposed to purchase Terns’ shares for $61 a pop, according to an SEC filing posted on Tuesday , resulting in a total offer of around $7.7 billion. This was in early February, at which point Terns was also fielding an acquisition offer from an unnamed “large pharmaceutical company,” which had proposed a per-share price of $58—an offer that it later raised to $61. Days after Merck’s initial proposal, Terns provided both of its suitors with updated clinical data from the Phase 1 CARDINAL study of TERN-701, an oral tyrosine kinase inhibitor being tested for chronic myeloid leukemia and the biotech’s lead asset. Tuesday’s SEC document did not detail what these updated findings were, revealing only that “the MMR [major molecular response] achievement rate was lower” than the 64% rate at 24 weeks that had previously been disclosed in a December 2025 presentation. MMR is a common bellwether for how effective a leukemia therapy is. Merck seemed underwhelmed by these new disclosures and lowered its proposed purchase price to $50 per share. “Merck believed that the MMR achievement rate for TERN-701 would likely be at the low end of the range discussed by Terns management,” the biotech reported in its securities filing. The unnamed bidder was similarly unimpressed with the updated CARDINAL data and withdrew its offer. The company “did not view TERN-701 as sufficiently differentiated or sufficiently de-risked to proceed,” according to Terns’ filing. Despite the downward adjustment in the purchase proposal, Merck nevertheless believed that TERN-701’s data were still “compelling,” Terns claimed on Tuesday. The biotech negotiated upward, and ultimately the parties settled on the final per-share price of $53, or $6.7 billion as announced last month. Leerink Partners agreed with Merck’s assessment. “We continue to think that the deal price underestimates the potential for TERN-701 in chronic myeloid leukemia,” the firm wrote to investors on Tuesday evening, projecting sales to reach “blockbuster levels” by 2032. At its peak, TERN-701 could hit global revenues of around $6.2 billion by 2040. When the transaction closes—which Leerink expects will happen in early May—Merck will gain a potential challenger to Novartis’ Scemblix, a kinase inhibitor approved in October 2021 for Philadelphia chromosome-positive chronic myeloid leukemia. The drug has already broken blockbuster status, bringing in more than $1.28 billion last year. The Terns deal also plays into Merck’s strategy of enriching its pipeline in preparation for the loss of exclusivity of mega-blockbuster cancer drug Keytruda. Market protections for the PD-1 inhibitor are set to expire in 2028 , after which the pharma expects biosimilars to eat away at its market share. Aside from the Terns takeover, Merck in November 2025 absorbed Cidara Therapeutics for $9.2 billion , winning over a late-stage antiviral drug, and acquired Verona Pharma for $10 billion in July that year for an FDA-approved chronic obstructive pulmonary disease drug Ohtuvayre. Patents 5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of the industry’s top-performers are losing key market protections. Some companies are more prepared than others. February 19, 2025 · 10 min read · Tristan Manalac Read more

Phase 1AcquisitionDrug Approval

07 Apr 2026

·endpoints.news

Merck got a peek at Terns' leukemia data during its deal talks — and decided to lower its bid by $1B

Although Merck and Terns Pharmaceuticals are part of biotech’s M&A surge, the $6.7 billion deal didn’t nearly play out the way either anticipated. Merck decided to significantly lower its offer for the biotech by about 13% after seeing updated clinical data that changed the outlook for Terns’ investigational oncology drug, called TERN-701, according to SEC filings on Tuesday. The documents show one of the rare instances in which a company drops its offer price during negotiations. The New Jersey pharma giant will gain access to an experimental chronic myeloid leukemia (CML) medicine that could one day compete with Novartis’ blockbuster treatment Scemblix. But the data led another potential acquirer, an unnamed “large pharmaceutical company” referred to as “Party C,” to back out of deal talks. Prior to this, a few other companies — Parties A, B, D and E — had told Terns that they weren’t interested in a deal, according to the regulatory paperwork . TERN-701, a small molecule, had served as the foundation of Terns’ turnaround last year. The biotech had originally set out to create fatty liver disease and metabolic disorder treatments, but abandoned its obesity prospect last year and went all in on the fight against cancer. Terns had projected a commercial launch of the leukemia prospect before 2031. During M&A talks, pharmaceutical companies and their biotech targets will usually negotiate for months before coming to a signed deal. Typically, those negotiations start at a lower point than what the pharma is willing to pay. The biotech is usually able to get the pharma to hike its offer at least once. On Dec. 23, Party C had made a $58 per-share offer for Terns. After crossing paths at the JP Morgan Healthcare Conference in January, Merck had come to Terns with an initial offer of $61 per share on Feb. 5. Party C then upped its offer to $61 per share, plus $9 per share in a contingent value right if TERN-701 was greenlit by the FDA for CML. But on the week of Feb. 9, the Foster City, CA-based biotech gave the companies updated data on the ongoing CARDINAL trial of TERN-701 as well as clinical data from its Chinese partner Hansoh Pharmaceutical. The SEC filings don’t spell out the exact clinical data update that Merck and Party C received. The documents reveal that the “MMR achievement rate was lower, potentially due to more patients being pre-treated with asciminib [Scemblix] in the evaluable population.” But the regulatory filing doesn’t detail the new achievement rate, other than saying it “stayed within Terns’ disclosed confidence interval after the ASH Annual Meeting, with no overlap with the asciminib interval.” On Feb. 16, a Party C representative called Terns CEO Amy Burroughs to let her know that the company would withdraw from discussions because it decided the updated TERN-701 data were “more nuanced than Party C had previously understood and that Party C did not view TERN-701 as sufficiently differentiated or sufficiently de-risked to proceed,” according to the Tuesday SEC filing. Merck, meanwhile, downsized its offer to $50 per share. Merck said that the “MMR achievement rate for TERN-701 would likely be at the low end of the range discussed by Terns management,” according to the Tuesday SEC filing. A Merck representative had told Terns it still viewed the data as “compelling relative to asciminib and therefore had continued enthusiasm to proceed with a transaction.” Terns was able to eke out a couple more dollars for the signed deal of $53 per share. That’s roughly a 13% decrease in deal value, or about $1 billion lower than Merck was willing to pay at the outset of talks. At the time of the March 25 deal disclosure, Leerink analysts questioned if Merck was “stealing” Terns at that deal value. Meanwhile, William Blair analyst Andy Hsieh had believed TERN-701 was being undervalued, writing in a note at the time that Merck’s offer “does not fully capture the potential” of the drug. When the companies announced the deal on March 25, Merck CEO Rob Davis called TERN-701 a “multibillion-dollar-plus opportunity.” Spokespeople for Merck and Terns didn’t immediately respond to requests for comment.

Acquisition

07 Apr 2026

·www.biopharmadive.com

Terns rebuffed a higher bid before selling to Merck

Terns Pharmaceuticals accepted a buyout from Merck & Co. last month that was worth 15% lower than a previous proposal, as updated study results led bidders to rework their offers, according to securities filings disclosed Tuesday.Four companies were in active talks about a potential deal, among them Merck and an unnamed Party C, those filings show. Yet Merck ultimately won out with a deal to buy the company for $53 a share, or $6.7 billion overall a relatively low purchase premium fueling debate that another bidder could yet emerge.Tuesdays filings shed some light on why that might not have happened yet.Weeks earlier, Party C bid $58 a share and then boosted its offer to $61 per share. That offer also included the possibility of another $9-per-share payout if Terns lead drug, called TERN-701, gained Food and Drug Administration approval in chronic myeloid leukemia within seven years. Merck answered with a $61 per share proposal a few weeks later, but without the added payout, known as a contingent value right.Big pharmas interest in Terns surged following the release of study data for TERN-701 at the American Society of Hematology meeting in December. Those findings have suggested TERN-701 might be superior to Novartis popular leukemia drug Scemblix.At the meeting, Terns executives met with two other drugmakers filings referred to as Party A and Party B. The $58-per-share proposal from Party C came weeks later, even though that firm hadnt discussed a potential deal with Terns beforehand. Terns board thought the offer was too low.Terns then met with several drugmakers, including Merck, at the J.P. Morgan Healthcare Conference in January. Party Cs top bid came about a week later, and CEO Amy Burroughs informed all previously interested competitors that the company was considering a bid.Parties A and B dropped out in early February, arguing that they didnt believe TERN-701 was worth paying a premium over the companys high share price at that time. Two others, Parties D and E, didnt participate in any detailed discussions.Merck made its $61 offer afterwards, and then along with Party C were given access to additional clinical data. That due diligence included updated TERN-701 results showing a lower response rate among treated patients than Terns had presented earlier.In mid-February, Party C dropped out, claiming that TERN-701s results were more nuanced than ... previously understood and that it no longer viewed the drug as sufficiently differentiated or de-risked.A committee of Terns board members also took the view that the drugs potential had dimmed somewhat and lowered their potential peak sales forecasts by 8%.Merck responded with a lower,$50 a share in mid-March after seeing the data. Burroughs then warned Terns board that shares would likely fall if a deal didnt come together.Terns made a counterproposal at $56 per share before accepting the bid that was announced publicly on March 25.Given the new information, “we now believe“ the deal will be completed this quarter “and that emergence of higher bidder is unlikely,“ wrote William Blair analyst Andy Hsieh, in a Tuesday client note. '

ASHAcquisition

100 Deals associated with Asciminib Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11403 D11404	-	-	DB12597

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation	United States	Novartis Pharmaceuticals Corp.	29 Oct 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	15 Jul 2022
Chronic Myelogenous Leukemia	Japan	Novartis Pharmaceuticals KK	28 Mar 2022
Philadelphia chromosome positive chronic myelogenous leukemia	United States	Novartis Pharmaceuticals Corp.	29 Oct 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Philadelphia positive acute lymphocytic leukaemia	Phase 3	United States	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Japan	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Argentina	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Austria	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Brazil	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Bulgaria	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Canada	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Czechia	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Denmark	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	France	Novartis Pharma AG	30 Aug 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2026	Not Applicable	Chronic Myelogenous Leukemia	291	Ponatinib	fuujgdftwn(semgezqgfc) = cunygjzkpl iasmfivkyw (qjwxdpscch )	Positive	21 Apr 2026
				Bosutinib	hdncdvraby(efvcghvxvx) = ukoxqinjvf cnxajmbfgx (ussffbbefj ) View more
NCT04216563 (CTgov)	Phase 2	Chronic phase chronic myeloid leukemia \| Residual Neoplasm \| Philadelphia chromosome positive chronic myelogenous leukemia	7	Asciminib	azoanqwvxj = iownexymwm cenntubkkl (kddxmwujuj, tpzrzstmqy - ziushrfgaj) View more	-	09 Jan 2026
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia Second line	392	Asciminib	zrpmfvpphf(uxtblwzuji) = vybsyhlqhw efnlnmcxph (twitiyujiv ) View more	Positive	06 Dec 2025
				ATP-competitive TKIs (dasatinib, nilotinib, bosutinib, imatinib)	zrpmfvpphf(uxtblwzuji) = mviurgxqws efnlnmcxph (twitiyujiv ) View more
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia	530	imatinib	lqzgkwcghz(aqiwqhgcpc) = geicidpxqn iixxbjztjn (tndnvcajnt ) View more	Positive	06 Dec 2025
				nilotinib	lqzgkwcghz(aqiwqhgcpc) = epkfjxwqbz iixxbjztjn (tndnvcajnt ) View more
NCT04971226 (ASC4FIRST, ASH2025)	Phase 3	Chronic Myelogenous Leukemia	415	Asciminib	wwsbdchzfe(fyovkqeojt) = ydxllyzhib cuskorpxam (kvihmezxvj ) View more	Positive	06 Dec 2025
				2G TKIs (dasatinib, nilotinib, bosutinib)	wwsbdchzfe(fyovkqeojt) = ayildkuhub cuskorpxam (kvihmezxvj ) View more
NCT05384587 (ASC2ESCALATE, ASH2025)	Phase 2	Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	101	Asciminib (ASC) 80 mg QD	wqwxabkqqg(pnrvrjxwfu) = vcwarcrvjz sfvyrocaep (uvcmufstzx ) View more	Positive	06 Dec 2025
NCT04971226 (ASC4FIRST, ASH2025)	Phase 4	Chronic phase chronic myeloid leukemia ASXL1 mutation	341	Asciminib	kzlepplpvn(aciodrdpnb) = ygfewohoix czyrgylhwf (auzzuyheil ) View more	Positive	06 Dec 2025
				Investigator-selected tyrosine kinase inhibitors (IS-TKI)	kzlepplpvn(aciodrdpnb) = etdcexlezk czyrgylhwf (auzzuyheil ) View more
ASH2025	Not Applicable	Chronic Myelogenous Leukemia	68	Asciminib	qirqejagdp(ljvhhdehyc) = mytujgvkhr phbzyywnfy (cqyafnowdz ) View more	Negative	06 Dec 2025
				Asciminib (Somatic mutations (SM) presence)	bgvitbrmjv(ayernnsorv) = eftymiemsg fndeinxzjh (ismdjrnrmk ) View more
ASH2025	Not Applicable	Philadelphia positive acute lymphocytic leukaemia	3,002	Asciminib-based therapy	mzdscvxmpw(ibipkrxdys) = 32.5% of pts had a clinical event with a diagnosis for pleural effusion, 17.0% for an arterial occlusive event (myocardial infarction, ischemic cardiovascular event, angina), and 70% for a gastrointestinal event (nausea, vomiting, constipation, diarrhea) vqloworijd (sebxkojhzt ) View more	Positive	06 Dec 2025
NCT05384587 (ASC2ESCALATE, ASH2025)	Phase 2	Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase First line	95	Asciminib (ASC)	mkarvymtri(btqbrouxik) = flzdpkyhno vmleuslksm (yazpieudhw ) View more	Positive	06 Dec 2025